By:
Robert Mason, President at Mason Law
Canadian public companies have a familiar menu of financing options, private placements, bought deals, public offerings, rights offerings. The right choice usually turns less on what is legally available and more on timing, certainty, dilution and the shareholder base.
May 2025 changes to the Listed Issuer Financing Exemption (LIFE) make that analysis more interesting.
Under coordinated blanket relief from the Canadian Securities Administrators, an eligible listed issuer can now raise the greater of $25 million or 20% of market capitalization, up to $50 million in any 12-month period, subject to dilution limits. The old cap was $10 million. That is a meaningful jump, and it pushes LIFE from a niche tool into a genuine alternative for mid-sized raises.
How it stacks up against the usual choices:
- Private placement: Targeted, flexible, efficient. Best where investors are known or the financing is strategic. Trade-off: resale restrictions, plus shareholder and exchange considerations around pricing, dilution, insider participation or control.
- Bought deal: Speed and certainty when market conditions and underwriter appetite cooperate. Pricing and timing track that appetite closely, and the window can move fast.
- Rights offering: Fairness-friendly to the existing register, but slower and often inefficient without a standby commitment or anchor investor.
- LIFE offering: No prospectus, freely tradeable securities, and now with limits that make it credible for larger raises. Still requires careful work on eligibility, disclosure, warrant terms and dilution caps.
LIFE is not a replacement for the others. It is an additional path that tends to shine where speed matters, a prospectus is not workable, and freely tradeable paper would help marketability.
The right question for boards and management is not “which exemption is available?” It is: which structure best fits the capital need, market window, shareholder dynamics and execution risk?
With the expanded LIFE limits, more Canadian issuers will find that the answer has changed.
For further guidance, see Robert Mason’s practice note Prospectus Exemptions and Resale Restrictions and the practice note Listed Issuer Financing Exemption, as well as additional resources in: Private Placements Resource Kit, Follow-On Offerings Resource Kit, and Rights Offerings Resource Kit.